TY - JOUR
T1 - CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1
AU - Rees, Elliott
AU - Walters, James T.R.
AU - Chambert, Kimberly D.
AU - O'Dushlaine, Colm
AU - Szatkiewicz, Jin
AU - Richards, Alexander L.
AU - Georgieva, Lyudmila
AU - Mahoney-Davies, Gerwyn
AU - Legge, Sophie E.
AU - Moran, Jennifer L.
AU - Genovese, Giulio
AU - Levinson, Douglas
AU - Morris, Derek W.
AU - Cormican, Paul
AU - Kendler, Kenneth S.
AU - O'neill, Francis A.
AU - Riley, Brien
AU - Gill, Michael
AU - Corvin, Aiden
AU - Sklar, Pamela
AU - Hultman, Christina
AU - Pato, Carlos
AU - Pato, Michele
AU - Sullivan, Patrick F.
AU - Gejman, Pablo V.
AU - Mccarroll, Steven A.
AU - O'donovan, Michael C.
AU - Owen, Michael J.
AU - Kirov, George
N1 - Funding Information:
The work at Cardiff University was funded by Medical Research Council (MRC) Centre (G0800509) and Program Grants (G0801418), the European Community’s Seventh Framework Programme (HEALTH-F2-2010-241909 (Project EU-GEI), an MRC PhD Studentship to E.R., a Clinical Research Fellowship to J.T.R.W. from the MRC/Welsh Assembly Government and the Margaret Temple Award from the British Medical Association. The 7129 SCZ samples from the ‘discovery sample’ were genotyped at the Broad Institute, USA, funded by a philanthropic gift to the Stanley Center for Psychiatric Research. Funding support for the Swedish study was provided by NIMH R01 MH077139 (P.S.), NIMH R01 MH095034 (P.S.), the Stanley Center for Psychiatric Research, the Karolinska Institu-tet, Karolinska University Hospital, the Swedish Research Council, anALFgrantfromSwedishCountyCouncil,theSöder-ström Königska Foundation and the Netherlands Scientific Organization (NWO 645-000-003). Funding to pay the Open Access publication charges for this article was provided by the MRC UK and the Wellcome Trust.
Funding Information:
We thank the participants and clinicians who took part in the Cardiff COGS study. For the CLOZUK sample, we thank Novar-tis for their guidance and co-operation. We also thank staff at The Doctor’s Laboratory, in particular Lisa Levett and Andrew Levett, for help and advice regarding sample acquisition. We acknowledge Kiran Mantripragada, Lesley Bates, Catherine Bresner and Lucinda Hopkins for laboratory sample management. We would like to acknowledge the contribution of data from outside sources: (i) Genetic Architecture of Smoking and Smoking Cessation accessed through dbGAP: Study Accession: phs000 404.v1.p1. Funding support for genotyping, which was performed at the Center for Inherited Disease Research (CIDR), was provided by 1 X01 HG005274-01. CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN2682007 82096C. Assistance with genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies (GENEVA) Coordinating Center (U01 HG004446). Funding support for collection of datasets and samples was provided by the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392) and the University of Wisconsin Transdisciplinary Tobacco Use Research Center (P50 DA019706, P50 CA084724). (ii). High-Density SNP Association Analysis of Melanoma: Case–Control and Outcomes Investigation, dbGaP Study Accession: phs00 0187.v1.p1. Research support to collect data and develop an application to support this project was provided by 3P50CA093459, 5P50CA097007, 5R01ES011740 and 5R01CA133996. (iii) Genetic Epidemiology of Refractive Error in the KORA Study, dbGaP Study Accession: phs000303.v1.p1. Principal investigators: Dwight Stambolian, University of Pennsylvania, Philadelphia, PA, USA; H. Erich Wichmann, Institut für Humangenetik, Helmholtz-Zentrum München, Germany, National Eye Institute, National Institutes of Health, Bethesda, MD, USA. Funded by R01 EY020483, National Institutes of Health, Bethesda, MD, USA. (iv) WTCCC2 study: Samples were downloaded from https://www.ebi.ac.uk/ega/ and include samples from the National Blood Donors Cohort, EGAD00000000024 and samples from the 1958 British Birth Cohort, EGAD00000000022. Funding for these projects was provided by the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/ 08/Z), the Wellcome Trust (072894/Z/03/Z, 090532/Z/09/Z and 075491/Z/04/B) and NIMH grants (MH 41953 and MH08 3094). (v) Molecular Genetics of Schizophrenia (MGS) study, Funding support for the Genome-Wide Association of Schizophrenia Study was provided by the National Institute of Mental Health (R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289 U01 MH46318, U01 MH79469 and U01 MH79470) and the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The datasets used for the analyses described in this manuscript were obtained from the database of Genotypes and Phenotypes (dbGaP) found at http://www.ncbi. nlm.nih.gov/gap through dbGaP accession numbers phs000 021.v3.p2 and phs000167.v1.p1. Samples and associated phenotype data for the Genome-Wide Association of Schizophrenia Study were provided by the Molecular Genetics of Schizophrenia Collaboration (PI: Pablo V. Gejman, Evanston Northwestern Healthcare (ENH) and Northwestern University, Evanston, IL, USA).
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Large and rare copy number variants (CNVs) at several loci have been shown to increase risk for schizophrenia. Aiming to discover novel susceptibility CNV loci, we analyzed 6882 cases and 11 255 controls genotyped on Illumina arrays, most of which have not been used for this purpose before. We identified genes enriched for rare exonic CNVs among cases, and then attempted to replicate the findings in additional 14 568 cases and 15 274 controls. In a combined analysis of all samples, 12 distinct loci were enriched among cases with nominal levels of significance (P < 0.05); however, none would survive correction for multiple testing. These loci include recurrent deletions at 16p12.1, a locus previously associated with neurodevelopmental disorders (P = 0.0084 in the discovery sample and P = 0.023 in the replication sample). Other plausible candidates include non-recurrent deletions at the glutamate transporter gene SLC1A1, a CNV locus recently suggested to be involved in schizophrenia through linkage analysis, and duplications at 1p36.33 and CGNL1. A burden analysis of large (>500 kb), rare CNVs showed a 1.2% excess in cases after excluding known schizophrenia-associated loci, suggesting that additional susceptibility loci exist. However, even larger samples are required for their discovery.
AB - Large and rare copy number variants (CNVs) at several loci have been shown to increase risk for schizophrenia. Aiming to discover novel susceptibility CNV loci, we analyzed 6882 cases and 11 255 controls genotyped on Illumina arrays, most of which have not been used for this purpose before. We identified genes enriched for rare exonic CNVs among cases, and then attempted to replicate the findings in additional 14 568 cases and 15 274 controls. In a combined analysis of all samples, 12 distinct loci were enriched among cases with nominal levels of significance (P < 0.05); however, none would survive correction for multiple testing. These loci include recurrent deletions at 16p12.1, a locus previously associated with neurodevelopmental disorders (P = 0.0084 in the discovery sample and P = 0.023 in the replication sample). Other plausible candidates include non-recurrent deletions at the glutamate transporter gene SLC1A1, a CNV locus recently suggested to be involved in schizophrenia through linkage analysis, and duplications at 1p36.33 and CGNL1. A burden analysis of large (>500 kb), rare CNVs showed a 1.2% excess in cases after excluding known schizophrenia-associated loci, suggesting that additional susceptibility loci exist. However, even larger samples are required for their discovery.
UR - https://www.scopus.com/pages/publications/84894375557
U2 - 10.1093/hmg/ddt540
DO - 10.1093/hmg/ddt540
M3 - Article
C2 - 24163246
AN - SCOPUS:84894375557
SN - 0964-6906
VL - 23
SP - 1669
EP - 1676
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 6
ER -